NCT04766645View on ClinicalTrials.gov

ACE2 Gender Differences in Stroke With COVID-19

CompletedOBSERVATIONAL
Enrollment

77

Participants

Timeline

Start Date

September 4, 2020

Primary Completion Date

December 16, 2022

Study Completion Date

January 31, 2023

Conditions
Neurologic Manifestations
Interventions
DEVICE

Robotic assisted intervention

Conventional rehabilitation and Robotic treatment of the upper limb (30 sessions, 5 times a week) using a set of 4 robotic devices: Motore (Humanware); Amadeo, Diego, Pablo (Tyromotion). The training will include motor-cognitive exercises specifically selected to train spatial attention, vision and working memory, praxis, executive function, and speed of processing.

GENETIC

epigenetic analyses

Epigenetic study: evaluation of methylation levels of ACE2 promoter and miR-200c-3p levels.

DIAGNOSTIC_TEST

biochemical analyses

Biochemical analysis: the evaluation of serum levels of angiotensin II, ACE2 and Vitamin D.

Trial Locations (1)

00168

Fondazione Don Carlo Gnocchi, Rome

All Listed Sponsors
lead

Fondazione Don Carlo Gnocchi Onlus

OTHER

NCT04766645 - ACE2 Gender Differences in Stroke With COVID-19 | Biotech Hunter | Biotech Hunter